https://www.leaderresearch.ca https://www.leaderresearch.ca/trials/hidradenitis-suppurativa-2 Phase 2 | Injection | 16 week treatment period | 8 week safety follow up For adults (≥18) with moderate to severe hidradenitis suppurativa (subcutaneous study drug <div data-rss-type="text"> <p> <span> Learn About This Trial </span> </p> </div> Tue, 18 Jun 2024 04:03:59 GMT https://www.leaderresearch.ca/trials/hidradenitis-suppurativa-2 https://www.leaderresearch.ca/trials/chronic-spontaneousurticaria-2 Phase 3 | Injection | 24 week treatment period | 8 week safety follow up For children and adults (≥6 to 80) with chronic spontaneous urticaria (subcutaneous study drug) <div data-rss-type="text"> <p> <span> Learn About This Trial </span> </p> </div> Tue, 18 Jun 2024 03:50:35 GMT https://www.leaderresearch.ca/trials/chronic-spontaneousurticaria-2